Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial

被引：32
|
作者：
Claggett, Brian [1 ]
Lachin, John M. [2 ]
Hantel, Stefan [3 ]
Fitchett, David [4 ,5 ]
Inzucchi, Silvio E. [6 ]
Woerle, Hans J. [7 ]
George, Jyothis T. [7 ]
Zinman, Bernard [5 ,8 ]
机构：
[1] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
[2] George Washington Univ, Biostat Ctr, Rockville, MD USA
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[4] St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Yale Univ, Endocrinol Sect, Sch Med, New Haven, CT USA
[7] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[8] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
CIRCULATION | 2018年 / 138卷 / 15期
关键词：
cardiovascular diseases; diabetes mellitus; empagliflozin;
D O I：
10.1161/CIRCULATIONAHA.118.033810
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1599 / 1601
页数：3
相关论文
共 50 条
  • [21] Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
    Antonio Ceriello
    Anne Pernille Ofstad
    Isabella Zwiener
    Stefan Kaspers
    Jyothis George
    Antonio Nicolucci
    Cardiovascular Diabetology, 19
  • [22] Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
    Ceriello, Antonio
    Ofstad, Anne Pernille
    Zwiener, Isabella
    Kaspers, Stefan
    George, Jyothis
    Nicolucci, Antonio
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [23] Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
    McGuire, Darren K.
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Fitchett, David
    Anker, Stefan D.
    Pocock, Stuart
    Kaspers, Stefan
    George, Jyothis T.
    von Eynatten, Maximilian
    Johansen, Odd Erik
    Jamal, Waheed
    Mattheus, Michaela
    Elsasser, Ulrich
    Hantel, Stefan
    Lund, Soren S.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (12): : 949 - 959
  • [24] Empagliflozin. Results of the EMPA-REG OUTCOME trial. A breakthrough in treatment of type 2 diabetes?
    Strojek, Krzysztof
    Rokicka, Dominika
    Szymborska-Kajanek, Aleksandra
    Wrobel, Marta
    CLINICAL DIABETOLOGY, 2016, 5 (03): : 107 - 110
  • [25] Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
    Cooper, Mark E.
    Inzucchi, Silvio E.
    Zinman, Bernard
    Hantel, Stefan
    von Eynatten, Maximilian
    Wanner, Christoph
    Koitka-Weber, Audrey
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 74 (05) : 713 - 715
  • [26] Empagliflozin's Cardiovascular Impact in High-Risk Patients With Type 2 Diabetes and Obstructive Pulmonary Disease: An Inquiry From EMPA-REG OUTCOME
    Anker, Stefan D.
    Fitchett, David H.
    Zinman, Bernard
    Ofstad, Anne Pernille
    Wanner, Christoph
    Vedin, Ola
    Schinzel, Birgit
    Yaggi, Henry K.
    George, Jyothis T.
    Sander, Leif Erik
    Inzucchi, Silvio E.
    Verma, Subodh
    CIRCULATION, 2020, 142
  • [27] Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
    Cherney, David Z. I.
    Zinman, Bernard
    Inzucchi, Silvio E.
    Koitka-Weber, Audrey
    Mattheus, Michaela
    von Eynatten, Maximilian
    Wanner, Christoph
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08): : 610 - 621
  • [28] Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
    Ferreira, Joao Pedro
    Verma, Subodh
    Fitchett, David
    Ofstad, Anne Pernille
    Lauer, Sabine
    Zwiener, Isabella
    George, Jyothis
    Wanner, Christoph
    Zinman, Bernard
    Inzucchi, Silvio E.
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [29] Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
    João Pedro Ferreira
    Subodh Verma
    David Fitchett
    Anne Pernille Ofstad
    Sabine Lauer
    Isabella Zwiener
    Jyothis George
    Christoph Wanner
    Bernard Zinman
    Silvio E. Inzucchi
    Cardiovascular Diabetology, 19
  • [30] The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
    Kaku, Kohei
    Wanner, Christoph
    Anker, Stefan D.
    Pocock, Stuart
    Yasui, Atsutaka
    Mattheus, Michaela
    Lund, Soren S.
    DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 662 - 674
12345